RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > 2020 > 3 > COVID-19 therapeutics tracker

COVID-19 therapeutics tracker

Posted 20 May 2022 | By Jeff Craven 

COVID-19 therapeutics tracker

A handful of therapeutics have been approved specifically to treat COVID-19, reduce its severity, or prevent it entirely. Among those treatments are dexamethasone, Avigan (favilavir), Veklury (remdesivir) alone and in combination with Olumiant (baricitinib), Lagevrio (molnupiravir), Xevudy (sotrovimab), Regkirona (regdanvimab), Ronapreve (casirivimab and imdevimab), amubarvimab and romlusevimab (formerly BRII-196 and BRII-198), Actemra/RoActemra (tocilizumab), Paxlovid (nirmatrelvir + ritonavir), and Kineret (anakinra). Evusheld (tixagevimab and cilgavimab; AZD7442) has been authorized in several countries for use as pre-exposure prophylaxis. Regulators around the world have allowed additional treatments to be used on an emergency-use basis.
A key focus in 2022 will be the efficacy of therapeutics against current and emergent SARS-CoV-2 variants. Therapeutics that are effective against one version of the virus, for example, may be significantly less effective or even ineffective against a new variant. Whenever possible, we will describe how these therapeutics work against the dominant variants circulating throughout the world.

This tracker will be updated biweekly with the latest in developments for treatment candidates who have advanced to at least Phase 1 study. If you notice an issue with this data or wish to submit an update, please email Regulatory Focus at news@raps.org.
Updated 20 May with new information on Paxlovid, Veklury (remdesivir), Xevudy (sotrovimab), Olumiant/Baricinix (baricitinib), and Gleevec/Glivec (imatinib).




© 2022 Regulatory Affairs Professionals Society.